A PYMNTS Company

Polpharma’s acquisition of Polfa Warszawa approved if three drugs divested

By  |  March 27, 2012

The UOKiK has granted conditional consent to ZakÅ‚ady Farmaceutyczne Polpharma’s takeover of ZakÅ‚ady Farmaceutyczne Polfa in Warszawa. Polpharma is owned by Genefar, and Polfa Warszawa is the state budget company belonging to Polski Holding Farmaceutyczny. Both companies are involved with the production and sale of pharmaceutical products.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The UOKiK found that the merger would lead to decreased competition in the markets for three antithrombotic drugs, as well as possible price increases. The terms of the consent thus require Polpharma to sell all its rights to three drugs within 18 months of the decision date. The drugs are: Polocard or Acard (antithrombotic drugs), Cipronex or Proxacin (fluorochinolones) and Sulfacetamidum natrium or Sulfacetamidum WZF 10% HEC.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Full content: UOKiK Press Release

     

    Related content: The AZ Judgment: A Green Light for Further Action on Pharma and IP (Sean-Paul Brankin, Crowell & Moring)